US20080287357A1 - Conjugate Comprising P21 Protein for the Treatment of Cancer - Google Patents

Conjugate Comprising P21 Protein for the Treatment of Cancer Download PDF

Info

Publication number
US20080287357A1
US20080287357A1 US11/911,427 US91142706A US2008287357A1 US 20080287357 A1 US20080287357 A1 US 20080287357A1 US 91142706 A US91142706 A US 91142706A US 2008287357 A1 US2008287357 A1 US 2008287357A1
Authority
US
United States
Prior art keywords
protein
conjugate
antennapedia
fusion protein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/911,427
Other languages
English (en)
Inventor
Agamemnon Epenetos
Christina Kousparou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trojan Technologies Ltd
Original Assignee
Trojan Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trojan Technologies Ltd filed Critical Trojan Technologies Ltd
Assigned to TROJAN TECHNOLOGIES LIMITED reassignment TROJAN TECHNOLOGIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EPENETOS, AGAMEMNON, KOUSPAROU, CHRISTINA
Publication of US20080287357A1 publication Critical patent/US20080287357A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Definitions

  • This invention relates to the P21 protein and conjugates and compositions comprising the P21 protein. These products are particularly useful in the treatment of cancer.
  • Cancer is one of the major causes of human mortality and has been the subject of intensive research. It is well known that almost all malignant tumours result from the transformation of a single cell into an immortal state, where the cell has lost the ability to control proliferation.
  • a cancer therapy will specifically target and destroy cancerous cells only.
  • a further problem that needs to be addressed is drug resistance resulting from chemotherapy.
  • the continued administration of a cytotoxic drug can cause a tumour, that was initially sensitive to the drug, to become increasingly drug resistant such that the drug loses its therapeutic efficacy.
  • Methods of improving the sensitivity of cancerous cells to drugs are therefore also required.
  • This invention is based on the finding that the P21 protein is useful in the treatment of cancer.
  • a synergistic effect is observed when the P21 protein is administered together with at least one other agent used in cancer therapy.
  • a conjugate comprises:
  • a composition comprises a conjugate comprising a first region comprising the P21 protein, or a homologue or functional fragment thereof, and a second region comprising a translocation factor, in combination with at least one drug.
  • a conjugate or composition according to the invention may be used as a medicament, particularly for the treatment of cancer.
  • the P21 protein or a homologue or functional fragment thereof may be used as a medicament, particularly for the treatment of cancer.
  • FIG. 1 illustrates the cytotoxicity of antennapedia/P21 fusion protein administered to the ovarian carcinoma cell line SKOV-3 and the osteosarcoma line SAOS-2, which were grown in 96-well ELISA dishes in conditions which resemble the situation in the human body;
  • FIG. 2 illustrates the cytotoxicity of the antennapedia/P21 fusion protein and its synergistic effect with cisplatin, and SKOV-3 cells;
  • FIG. 3 illustrates the cytotoxicity of the antennapedia/P21 fusion protein in combination with cisplatin and taxol, on SKOV-3 cells, indicating that the antennapedia/P21 fusion, cisplatin and taxol act synergistically when used in combination;
  • FIG. 4 illustrates the clearance from the blood of purified, radiolabelled antennapedia protein (4A) and antennapedia-P21 fusion protein (4B) in tumour-free mice;
  • FIG. 5 illustrates the organ-to-blood ratios and the protein accumulation in various organs, for the antennapedia protein (5A) and antennapedia-P21 fusion protein (5B);
  • FIG. 6 illustrates the reduction in the growth of tumours using antennapedia/P21 fusion protein
  • FIG. 7 is a Kaplan-Meier survival curve indicating the survival of mice is greatest when receiving the antennapedia/P21 fusion protein at its highest concentration
  • FIG. 8 demonstrates a synergistic effect in vivo when using the antennapedia/P21 fusion protein, taxol and cisplatin.
  • FIG. 9 illustrates the Kaplan-Meier survival curve for mice receiving the antennapedia/P21 fusion protein and chemotherapy, it is clear that the best survival benefit is demonstrated by the animals receiving both the fusion protein and supplementary chemotherapy;
  • FIG. 10 illustrates the Kaplan-Meier survival curves for mice receiving the antennapedia/P21 fusion and animals also receiving cisplatin and taxol.
  • FIG. 11 shows the Kaplan-Meier survival curves for mice receiving the antennapedia/P21 fusion and an additional chemotherapeutic.
  • the invention utilises the P21 protein as a therapeutic agent.
  • the P21 protein may be used as a therapeutic agent alone or in combination with other therapeutic agents. When used in combination with other therapeutic agents, a surprising synergy is observed.
  • the P21 protein is attached to a translocation factor, to enable the P21 protein to enter a target cell.
  • P21 could be used extensively in cancer therapy. Most cancers result from mutations in the P53 gene, which is therefore the obvious, and most favoured, target when designing cancer therapeutics.
  • the P21 protein which functions further down the apoptotic cascade, has not been considered as a therapeutic agent.
  • the present invention bypasses P53 and allows the direct delivery of active P21, for the treatment of cancer.
  • the administration of P21 and a chemotherapeutic provides a surprising improvement in anti-cancer therapy.
  • protein refers to a polymer molecule comprising a plurality of amino acid residues linked via the peptide linkage, as will be appreciated by one skilled in the art. Peptides and polypeptides are encompassed with the term “protein”.
  • SEQ ID NO.1 SEPAGDVRQN PCGSKACRRL FGPVDSEQLS RDCDALMAGC IQEARERwNF DFVTETPLEG DFAWERVRGL GLPKLYLPTG PRRGRDELGG GRRPGTSPAL LQGTAEEDHV DLSLSCTLVP RSGEQAEGSP GGPGDSQGRK RRQTSMTDFY HSKRRLIFSK RKP
  • the annotated human P21 sequence can be found in the SWISSPROT database with the primary accession number P38936 (Entry Name CDN1A_HUMAN). Although the human sequence (SEQ ID NO. 1) is preferred, a P21 protein from any species may be used according to the invention, for example the Mus musculus protein (SWISSPROT primary accession number P39689) or the Felis silvestris catus (Cat) protein (SWISSPROT primary accession number 019002). A polynucleotide encoding a P21 protein is also within the scope of the invention.
  • Functional variants i.e. homologues
  • fragments of the human P21 protein SEQ ID No. 1
  • proteins with high levels e.g. greater than 60%, preferably greater than 70%, more preferably greater than 80% and most preferably greater than 90%, e.g. greater than 95%) of sequence similarity to SEQ ID NO. 1 are within the scope of the present invention.
  • similarity is known in the art. The term refers to a comparison between amino acid sequences, and takes into account not only identical amino acids in corresponding positions, but also functionally similar amino acids in corresponding positions. Similarity between polypeptide sequences therefore indicates functional similarity, in addition to sequence similarity.
  • Levels of similarity between amino acid sequences can be calculated using known methods.
  • Publicly available computer-based methods for determining similarity include the BLASTP, BLASTN and FASTA programs, the BLASTX program available from NCBI, and the Gap program from Genetics Computer Group, Madison Wis.
  • Levels of similarity referred to herein may, for example, be determined using the Gap program, with a Gap penalty of 12 and a gap length penalty of 4.
  • Variants or fragments of P21 may be produced using standard recombinant DNA techniques such as site-directed mutagenesis, as will be apparent to the skilled person based on conventional protein technology. Fragments or homologues of the P21 protein should retain the function of the native P21 protein, i.e. should be a “functional” fragment or homologue. The function that must be retained is the ability to act as a tumour-suppressor protein, and block cycD/CDK4 complex formation, and therefore cause G1 arrest of a eukaryotic cell. Tests for cell division and viability are well-known in the art, for example the CellTiter 96® and CytoTox 96® assays available from Promega Corp., Wisconsin USA.
  • the P21 protein is associated with a translocation factor, forming a conjugate.
  • conjugate refers to a chimeric molecule formed from a translocation factor and a P21 protein.
  • the conjugate is therefore a hybrid molecule not found together in their natural form.
  • the formation of a conjugate does not reduce or otherwise adversely affect the ability of the P21 protein or the translocation factor to function as intended.
  • translocation refers to the delivery of a protein across a cell membrane. It will be apparent to one skilled in the art that a translocation factor is required to deliver the P21 protein to a target cell.
  • translocation factor refers to any moiety that has the ability to translocate across a cell membrane, i.e. an outer cell membrane. When the P21 protein is associated with the translocation factor in a conjugate, P21 is also translocated across the cell membrane.
  • the translocation factor will preferably be a protein.
  • a number of proteins with the ability to translocate cell membranes are known in the art, including histone proteins, the herpes simplex virus VP22 protein and HIV tat domain.
  • the tat protein from HIV-type I comprises 86 amino acids encoded by two exons. The first 72 amino acids are encoded by exon 1 and exhibit full trans-activating activity. A cluster of basic amino acid residues in this region are known to be able to translocate across a cell membrane. This cluster, contained within amino acid residues 37-72, is within the scope of the invention. More specifically, amino acids 49-58 are a preferred translocation factor as disclosed by Vives et al., J. Biol. Chem: 272 (1997); 25: pp 16010-16017, which is incorporated herein by reference. Amino acids 49-58 of HIV TAT are listed below, as SEQ ID NO. 2:
  • any fragment or homologue of the HIV-type 1 tat protein, that retains the ability to translocate a cell membrane, is within the scope of the invention.
  • the homeodomain of the Drosophila antennapedia protein is used as the translocation factor.
  • Functional variants and homologues of the antennapedia homeodomain may also be used, provided that they maintain the ability to translocate.
  • a full description of the antennapedia homeodomain translocation factor is given in WO-A-99/11809, the content of which is incorporated herein by reference.
  • the homeodomain of the Antp gene is shown in SEQ ID No. 3.
  • the amino acid sequence of the Drosophila antennapedia protein contains a motif of approximately 60 amino acids, known as the homeodomain, which has the ability to function as a translocation factor.
  • the full-length protein, homeodomain or any homologue or fragment (of the protein or homeodomain) that maintains the ability to translocate, may be used as a translocation factor in the present invention.
  • a homologue preferably comprises a region with a high level (eg greater than 60%, preferably greater than 70%, more preferably greater than 80% and most preferably greater than 90%, e.g. 95% or more) of sequence similarity to the Drosophila antennapedia homeodomain.
  • Drosophila homeodomain and antennapedia full-length protein are preferred, one skilled in the art will realise that functional homologues may originate from any organism.
  • Antennapedia homologues have been found in the majority of multicellular organisms and are well conserved.
  • the human and drosophila homeodomains differ by only one conservative amino acid substitution.
  • Homologues produced artificially, for example using site-directed mutagenesis are also within the scope of the invention. The ability of a naturally-occurring or artificial sequence to translocate the membrane may be tested by routine methods that are well-known in the art.
  • EP-B-0 485 578 to CNRS discloses homeopeptides comprising the helix 3 sequence of pAntp, and these are incorporated herein by reference.
  • WO97/12912 also to CNRS discloses the actual sequence of the helix 3 of pAntp, and variants thereof. These also are incorporated herein be reference. In particular, helix 3 is said to have the sequence:
  • SEQ ID NO. 4 Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn- Arg-Arg-Met-Lys-Trp-Lys-Lys
  • the variants are said to have the sequence:
  • SEQ ID NO. 5 X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11- X12-X13-X14-X15-X16 or SEQ ID NO. 6: X16-X15-X14-X13-X12-X11-X10-X9-X8-X7- X6-X5-X4-X3-X2-X1
  • each X represents an ⁇ -amino acid, with X6 representing tryptophan; said peptide comprising between 6 and 10 hydrophobic amino acids.
  • the P21 protein and translocation factor are covalently linked.
  • the covalent linkage may be in the form of a chemical linker molecule.
  • the P21 protein and translocation factor are produced as a single fusion protein.
  • the P21 protein and translocation factor may be in any order. It is preferred that the translocation factor is located at the amino terminal end of the P21 protein.
  • Methods of producing fusion proteins are well known in the art, using standard recombinant nucleic acid procedures, as described in Sambrook et al, Molecular Cloning: A Laboratory Manual (Cold Spring Harbour Laboratory Press), the content of which is incorporated herein by reference. Nucleic acids encoding a fusion protein are within the scope of the invention, as are expression vectors comprising the nucleic acid encoding the fusion protein and at least one promoter region.
  • the conjugate comprising the P21 protein and a translocation factor can be included in a composition additionally containing at least one drug.
  • the drug is used in cancer therapy.
  • the drug is a chemotherapeutic, for example, cisplatin or taxol.
  • other drugs that are used in cancer therapy may also be combined with a conjugate according to the invention, for example anti-inflammatory drugs, antibodies (including monoclonal antibodies), immunomodulating drugs, hormones and hormone antagonists, antibacterials, antifungals and antivirals. Non-limiting examples are given below.
  • Cytotoxic Drugs/Cytostatics alkylating agents (e.g. cyclophosphamide, melphalan etc.), cytotoxic antibiotics (doxorubicin, epirubicin, bleomycin, mitomycin etc.), antimetabolites (methotrexate, capecitabine, gemcitabine, fluorouracil, vinca alkaloids and etoposide (vinblastine, vincristine etc.), platinum compounds (carboplatin, cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel etc), topoisomerase I inhibitors (irinotecan, topotecan etc.).
  • alkylating agents e.g. cyclophosphamide, melphalan etc.
  • cytotoxic antibiotics doxorubicin, epirubicin, bleomycin, mitomycin etc.
  • antimetabolites metalhotrexate, capecitabine, gemcitabine, fluorouracil,
  • Immune Response Modifiers antiproliferative immunosuppressants, corticosteroids.
  • Immunomodulators interferons, interleukins.
  • Monoclonals transtuzumab, rituximab, alemtuzumab.
  • Antibacterial drugs penicillins, cephalosporins, cephamycins, tetracyclins, macrolides, aminoglycosides, other antibacterials (chloramphenicol, fusidic acid, vancomycin etc).
  • Hormones thyroid hormones, oestrogens, progesterones, androgens, and all their antagonists.
  • Others vitamins, non-steroidal anti-inflammatory drugs (e.g. celecoxib, rofecoxib etc), vaccines, antisera, antifungal drugs, antiviral drugs and steroids.
  • the P21 protein or a homologue or functional fragment thereof, or a conjugate as described above may be used in the treatment of cancer.
  • a composition comprising the P21 protein or a conjugate as described above and an additional drug is used in the treatment of cancer.
  • a pharmaceutical composition containing the active component may be in any suitable form. It is preferred that the P21 protein or conjugate is in a form suitable for transdermal or intravenous administration. Suitable pharmaceutically-acceptable buffers, excipients, diluents etc. may also be present, as well be appreciated by the skilled person.
  • the composition may be in a form intended for administration directly to the diseased tissue or maybe in a form that is targeted indirectly to the diseased tissue.
  • Dosage levels of the order of from about 0.1 mg to about 25 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 8 mg to about 2 g per patient per day).
  • the patient may be effectively treated by the administration of from about 0.25 to 12.5 mg of the P21 compound per kilogram of body weight per day (about 20 mg to about 1 mg per patient per day).
  • Dosage unit forms will generally contain between from about 1 mg to about 500 mg of active ingredient.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
  • the P21 compound can be delivered to the site of the disease by mechanical means, or targeted to the site of the disease through the use of systemic targeting technologies such as liposomes (with or without chemical modification that provides them with affinity for the diseased tissue), antibodies, aptamers, lectins, or chemical ligands with affinity for aspects of the diseased tissue that are less abundant or not present on normal tissue.
  • systemic targeting technologies such as liposomes (with or without chemical modification that provides them with affinity for the diseased tissue), antibodies, aptamers, lectins, or chemical ligands with affinity for aspects of the diseased tissue that are less abundant or not present on normal tissue.
  • Bacterial plasmid clones were constructed for the expression of the P21 protein alone or as a fusion to the antennapedia peptide. Expression of the ANTP-P21 fusion (the “fusion protein”) was maximal three hours post induction, after which protein purification under denaturing conditions with Guanidinium Hydrochloride and Urea followed. During renaturation and refolding, protein precipitation was observed. This suggested that various buffers needed to be tested. Five buffers were tried; 20 mM Tris-base/0.5 M NaCl/0.1% Tween-20 pH 8 kept the protein in solution.
  • the production of the fusion protein allowed a cell translocation experiment to be performed, to test the ability of the antennapedia-containing fusion protein to translocate across biological membranes.
  • Two cell lines were used in this experiment, ASPC1 and HeLa (ASPC1—human pancreatic adenocarcinoma, HeLa—human cervical adenocarcinoma).
  • the protein was incubated for 10 and 60 min on cells in various dilutions at 37° C. Translocation of the fusion protein was evident in both cell lines, even after only ten minutes of incubation. P21 protein alone did not appear to translocate across cells. Protein internalisation was even evident after incubation at 4° C., suggesting an energy-independent mechanism of translocation not involving classical endocytosis.
  • the ovarian carcinoma cell line SKOV-3 and the osteosarcoma line SAOS-2 were grown in 96-well ELISA dishes in conditions which resemble the situation in the human body (tissue culture facility).
  • Fusion protein and P21 alone were given to the cells at 50 mg/ml for 24 and 48 hours.
  • the controls included untreated cells to give the background cell death; cells to which only Guanidinium Hydrochloride was added; and cells which were totally lysed with detergent in order to give 100% cell death.
  • the experiment was terminated at 24 and 48 hours and plates were assessed for apoptotic cell death.
  • the proteins were then applied to the cell cultures. Significant cell death was observed in two cancer cell lines on administration of the fusion protein as shown in FIG. 1 .
  • Taxol disrupts the dynamic equilibrium within the microtubule system and blocks cells in the late G2 phase and M phase of the cell cycle, inhibiting cell replication. Results indicate a synergistic effect between the three modes of therapy, and an enhanced cytotoxic effect in the presence of the drugs along with the fusion protein at relatively low concentrations.
  • FIG. 3 Data which demonstrates the killing ability of the fusion protein together with its synergistic effect with the other killing agents is shown in FIG. 3 .
  • the Antp-P21 fusion protein resulted in increased cell death when incubated with the cytotoxic agents cisplatin and taxol.
  • Antp-P21, cisplatin and taxol act synergistically when used in combination.
  • the antennapedia protein appeared to have a rapid initial clearance, but it took more than fifteen hours to clear completely from the circulation. This behaviour is expected from positively-charged proteins. This interval should allow sufficient time for it to exit the blood vessels and accumulate in tissues. After dissecting out and counting all organs and tissues of the mice, the organ-to-blood ratios and the protein accumulation in various organs was calculated; as shown in FIG. 5A .
  • the protein did not have an affinity for any particular type of tissue. It appeared to accumulate in highly vascularised tissues.
  • FIGS. 4B and 5B The kinetics and biodistribution of purified, radiolabelled, antennapedia-P21 fusion protein in tumour-free mice were then tested. The results are shown in FIGS. 4B and 5B .
  • the fusion protein appeared to have a rapid initial clearance, but to take more than seventeen hours for it to clear completely from the circulation ( FIG. 4B ). This behaviour resembled that observed when the antennapedia protein alone was tested, and was expected from positively-charged proteins. This interval was expected to allow sufficient time for it to exit the blood vessels and accumulate in tissues. After dissecting out and counting all organs and tissues of the mice, we were able to calculate the organ-to-blood ratios and to plot the biodistribution of the protein, as illustrated in FIG. 5B .
  • the fusion protein did not have an affinity for any particular type of tissue, as expected. It appeared to accumulate in highly vascularised tissues. Experiments were performed which allowed us to locate the protein in the tissues by staining with anti-protein antibodies (anti-HIS antibody—Qiagen). These immunohistochemistry studies were performed on frozen tissue sections.
  • Results showed that the fusion protein accumulated in major organs, as indicated in Table 1, and was found as a full-length molecule. The behaviour of the molecule is likely to remain essentially unaltered in tumour-bearing mice, with the exception of it accumulating in large amounts in the actual tumour.
  • tumour-bearing animals which indicated the optimal time of protein accumulation in the tumour and therefore the time it takes for the fusion protein to exit the blood circulation and enter the neighboring tissues. This information is desirable when designing experiments which were to involve repeated doses and time interval between each dose.
  • Radiolabelled fusion protein was administered as a single dose via the tail vein to tumour-bearing mice and tumours examined at various time points. Results demonstrated that the optimal time of tumour localization was three hours after administration. After this period, staining intensity and therefore protein quantity decreased. Results are selectively shown in the following tables:
  • T 15 MIN SKOV-3 tumour-bearing female nude mouse injected with 25 ⁇ g of I 125 -labelled Antennapedia-P21 fusion protein via tail vein. Essentially no staining observed. % i.d./g tissue 3.2211
  • T 1 hour SKOV-3 tumour-bearing female nude mouse injected with 25 ⁇ g of I 125 -labelled Antennapedia-P21 fusion protein via tail vein. Diffuse staining observed throughout the cells. % i.d./g tissue 1.7389
  • TABLE 4 3 hours SKOV-3 tumour-bearing female nude mouse injected with 25 ⁇ g of I 125 -labelled Antennapedia-P21 fusion protein via tail vein. Nuclear localization observed. This is the time point at which maximal staining is observed. % i.d./g tissue 1.4930
  • T 6 hours SKOV-3 tumour-bearing female nude mouse injected with 25 ⁇ g of I 125 -labelled Antennapedia-P21 fusion protein via tail vein. Staining intensity decreased. Fusion protein is possibly degraded intracellularly. % i.d./g tissue 1.1064
  • tumour-bearing mice The maximum tolerated dose which can be safely administered to tumour-bearing mice was then tested. Three different concentrations of the fusion protein was tested, as well as controls, both intravenously and intratumourally. Animals were monitored for signs of distress and toxicity, and measurements of tumour diameter, mice weight and white blood cell count were recorded. The concentration of 2.5 mg/ml of fusion protein was shown to be the highest which can be used without toxicity effects in a repetitive manner and was therefore used in subsequent studies.
  • SKOV3 ovarian adenocarcinoma-bearing xenografts were used.
  • the Antennapedia-P21-treated animals were in large groups of 8 animals, and the experiment included controls such as 8 animals receiving saline solution and 8 animals receiving increasing doses of the Antennapedia protein only.
  • Six injections were performed on a weekly basis. Day zero shown in FIG. 6 is the first day of the injections.
  • a survival profile which supported further the mode of action of our therapeutic agent was identified.
  • the benefit of treatment in small-tumour animals is higher than in animals with larger tumours.
  • Penetration and therapeutic effect of proteins has been shown to be improved in smaller tumours. The rationale behind this is that the interstitial pressure is higher in the core of large tumours and the environment is more difficult for non-targeted molecules to penetrate. Therefore, therapeutic benefit was higher in smaller tumours with lower interstitial pressure.
  • the Kaplan-Meier survival curve for the animals receiving the fusion protein and chemotherapy is given in FIG. 9 . It is evident that the best survival benefit was demonstrated by the animals receiving both the fusion protein and supplementary chemotherapy.
  • the fusion protein Antennapedia-P21 was tested in nude mice xenografted with colon carcinoma RKO-E6 cells. These cells contain a stably integrated human papilloma virus (HPV) E6 oncogene under the control of the cytomegalovirus (CMV) promoter.
  • HPV E6 oncogene causes a decrease in normal p53 levels and functions, to the extent that this line lacks appreciable functional p53.
  • the RKO-E6 cell line has been used frequently to investigate the effects of p53 loss on cellular parameter such as p53-mediated transcription and apoptosis. In the experiments described here, it has been used to study the effects of administering P21 to cells, therefore by-passing the need for p53 activation. Apoptosis is measured as tumour cell death and tumour size reduction.
  • mice were xenografted with RKO E6 tumours, randomized into four groups and administered one of the following via tail vein injection:
  • Chemotherapeutic drugs were administered in doses previously documented to cause measurable tumour reductions. Tumour regression was evaluated, which in turn was translated into a survival benefit.
  • Results are shown in FIG. 11 . reatment with PBS, Fusion protein or Chemotherapy alone had little effect on overall survival, with a median survival in the range of 30 days for all these groups. A significant improvement in survival was observed in animals treated with the Fusion in combination to Chemotherapy, with a median survival of 45 days, demonstrating synergistic interactions.
  • the Antennapedia-P21 fusion protein is expected to have such an effect since administration of it has previously been shown to result in its accumulation in various tissues, and because its application has been shown not to be limited by a dose-dependent toxicity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/911,427 2005-04-14 2006-04-18 Conjugate Comprising P21 Protein for the Treatment of Cancer Abandoned US20080287357A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0507598.1 2005-04-14
GB0507598A GB0507598D0 (en) 2005-04-14 2005-04-14 Composition
PCT/GB2006/001407 WO2006109092A1 (en) 2005-04-14 2006-04-18 Conjugate comprising p21 protein for the treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001407 A-371-Of-International WO2006109092A1 (en) 2005-04-14 2006-04-18 Conjugate comprising p21 protein for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/608,718 Continuation US9145446B2 (en) 2005-04-14 2009-10-29 Conjugate comprising P21 protein for the treatment of cancer

Publications (1)

Publication Number Publication Date
US20080287357A1 true US20080287357A1 (en) 2008-11-20

Family

ID=34611144

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/911,427 Abandoned US20080287357A1 (en) 2005-04-14 2006-04-18 Conjugate Comprising P21 Protein for the Treatment of Cancer
US12/608,718 Active 2028-03-12 US9145446B2 (en) 2005-04-14 2009-10-29 Conjugate comprising P21 protein for the treatment of cancer
US14/861,923 Active US10259852B2 (en) 2005-04-14 2015-09-22 Conjugate comprising P21 protein for the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/608,718 Active 2028-03-12 US9145446B2 (en) 2005-04-14 2009-10-29 Conjugate comprising P21 protein for the treatment of cancer
US14/861,923 Active US10259852B2 (en) 2005-04-14 2015-09-22 Conjugate comprising P21 protein for the treatment of cancer

Country Status (16)

Country Link
US (3) US20080287357A1 (ja)
EP (1) EP1869185B1 (ja)
JP (1) JP4955654B2 (ja)
KR (1) KR20080016798A (ja)
CN (1) CN101194017B (ja)
AT (1) ATE458819T1 (ja)
AU (1) AU2006235742B2 (ja)
CA (1) CA2604536A1 (ja)
DE (1) DE602006012463D1 (ja)
DK (1) DK1869185T3 (ja)
ES (1) ES2343972T3 (ja)
GB (1) GB0507598D0 (ja)
PL (1) PL1869185T3 (ja)
PT (1) PT1869185E (ja)
SI (1) SI1869185T1 (ja)
WO (1) WO2006109092A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014310360B2 (en) * 2013-06-11 2019-10-24 PPL (BVI) Limited Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CN110511273B (zh) * 2019-07-12 2021-06-01 福州市皮肤病防治院 一种细胞穿膜多肽的制备方法及其应用
CN110850104B (zh) * 2020-01-15 2020-06-05 上海众启生物科技有限公司 用于阿尔兹海默症自身抗体检测的蛋白抗原组合及其应用
GB202019864D0 (en) 2020-12-16 2021-01-27 Anastasis Biotec Ltd Improved cell-penetrating peptides and fusion proteins
CN112961865B (zh) * 2021-02-22 2023-06-02 广西大学 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用
AR127912A1 (es) * 2021-12-08 2024-03-06 Ferring Bv Método de purificación de proteínas por precipitación

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068706A1 (en) * 1996-01-23 2002-06-06 Jeno Gyuris Inhibitors of cell-cycle progression and uses related thereto
US6521602B1 (en) * 1999-03-01 2003-02-18 Gpc Biotech Inc. Anti-neoplastic compositions and uses thereof
US20030133971A1 (en) * 1991-12-16 2003-07-17 Smith James R. Senescent cell-derived inhibitors of DNA synthesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003284D0 (en) * 2000-02-15 2000-04-05 Secr Defence Brit Anti-viral therapy
IL151910A0 (en) * 2000-04-12 2003-04-10 Implyx Ltd Compositions for drug delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133971A1 (en) * 1991-12-16 2003-07-17 Smith James R. Senescent cell-derived inhibitors of DNA synthesis
US20020068706A1 (en) * 1996-01-23 2002-06-06 Jeno Gyuris Inhibitors of cell-cycle progression and uses related thereto
US6521602B1 (en) * 1999-03-01 2003-02-18 Gpc Biotech Inc. Anti-neoplastic compositions and uses thereof

Also Published As

Publication number Publication date
US9145446B2 (en) 2015-09-29
PL1869185T3 (pl) 2010-10-29
CN101194017B (zh) 2013-08-28
WO2006109092A1 (en) 2006-10-19
KR20080016798A (ko) 2008-02-22
JP2008535512A (ja) 2008-09-04
AU2006235742A1 (en) 2006-10-19
ATE458819T1 (de) 2010-03-15
AU2006235742B2 (en) 2011-07-14
JP4955654B2 (ja) 2012-06-20
DK1869185T3 (da) 2010-06-21
EP1869185A1 (en) 2007-12-26
CN101194017A (zh) 2008-06-04
US10259852B2 (en) 2019-04-16
US20160068582A1 (en) 2016-03-10
EP1869185B1 (en) 2010-02-24
GB0507598D0 (en) 2005-05-18
PT1869185E (pt) 2010-05-28
ES2343972T3 (es) 2010-08-13
US20110021441A1 (en) 2011-01-27
CA2604536A1 (en) 2006-10-19
DE602006012463D1 (de) 2010-04-08
SI1869185T1 (sl) 2010-09-30

Similar Documents

Publication Publication Date Title
US10259852B2 (en) Conjugate comprising P21 protein for the treatment of cancer
JP6030622B2 (ja) 癌の阻害剤としてのｍｕｃ−１細胞質ドメインペプチド
Dietz et al. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction
US8841414B1 (en) Targeted delivery of therapeutic peptides by thermally responsive biopolymers
CN105378084B (zh) 用于治疗癌症的方法和组合物
EP1856145B1 (en) Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis
CN109563151A (zh) 用于治疗癌症的方法和组合物
JP4887143B2 (ja) 癌細胞を選択的に死滅させるＲａｓＧＡＰ由来ペプチド
US9314497B2 (en) E2F as a target of hormone refractory prostate cancer
CN102993314B (zh) 一种抗肿瘤融合蛋白及其制备方法和用途
Kousparou et al. Generation of a selectively cytotoxic fusion protein against p53 mutated cancers
US20190030126A1 (en) Inhibitors of the Interaction BCL-2 L10 / IP3 Receptors
WO2018152446A2 (en) Cell-penetrating atf5 polypeptides and uses thereof
US20220354957A1 (en) Peptides targeting macrophages, and conjugates, compositions, and uses thereof
CA3153060A1 (en) Peptides targeting macrophages, and conjugates, compositions, and uses thereof
Sibuyi Development of a receptor targeted nanotherapy using a proapoptotic peptide
Mikecin The effect of thermally targeted p21-mimetic polypeptide on androgen independent prostate cancer cell lines

Legal Events

Date Code Title Description
AS Assignment

Owner name: TROJAN TECHNOLOGIES LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EPENETOS, AGAMEMNON;KOUSPAROU, CHRISTINA;REEL/FRAME:021121/0489

Effective date: 20071219

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION